Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission.
- 1Department of Paediatrics, Maulana Azad Medical College & Associated Lok Nayak Hospital, New Delhi, India.
- 2Department of Microbiology, Maulana Azad Medical College & Associated Lok Nayak Hospital, New Delhi, India.
Abstract
Background and objectives Varicella-zoster (VZV) virus infection can be severe in children with nephrotic syndrome. Lack of varicella vaccination through the national immunisation programme in India leaves many vulnerable to infection. We conducted this study to document the seroprevalence of Varicella antibodies in patients with nephrotic syndrome. Methods This cross-sectional study (Oct 2024-May 2025) was conducted at a tertiary-care teaching hospital in India, in children (1-18 y) with nephrotic syndrome (both steroid-sensitive and steroid-resistant) in disease remission. Serum VZV IgG antibodies were measured using the EUROIMMUN ELISA kit; titres ≥100 IU/L were considered seroprotective. Results 100 patients were enrolled (median age 8 y). None had received varicella vaccination, and only two reported prior infection. Overall seroprotection was 22% with a geometric mean titre of 9.472 IU/L [median (IQR) 7.59 (3.35; 73.38) IU/L]. No significant difference was observed in titres between steroid-sensitive and steroid-resistant nephrotic syndrome (P=0.532), but seroprotection increased with age (11.1% in <5 y to 33.3% in >10 y). Interpretation and conclusions Low seroprevalence likely reflects the inadequacy of natural immunity and absence of routine varicella vaccination, warranting larger seroprevalence studies and future research on the need for priority immunisation for this high-risk population.
Related
- Seroprevalence and risk factors for SARS-CoV-2 infection among unvaccinated adults in a rural community in South-East Nigeria during the Omicron era: a community-based cross-sectional study
- Seroprevalence of IgG antibodies against measles in adolescents and adults from Metropolitan Lima and Callao, Peru, 2024-2025
- Seroprevalence of Japanese encephalitis virus and other flavivirus-specific antibodies among Australian blood donors following a novel epidemic spread of Japanese encephalitis virus: a cross-sectional study
- Seroprevalence of measles-specific IgM and IgG antibodies among children (0–12 years) with measles-like symptoms: a hospital-based cross-sectional study in Northeast Nigeria
- Recognizing a Forgotten Disease: A Case Report of Tetanus in an Unvaccinated Adolescent
BibTeX
@article{bharathidasan2026seroprevalence,
title = {{Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission.}},
author = {Bharathidasan B and Malika Yadav and Aashima Dabas and Anju Sharma and Vikas Manchanda and Mukta Mantan},
journal = {The Indian journal of medical research},
year = {2026},
month = aug,
doi = {10.25259/ijmr_734_2026},
url = {https://europepmc.org/article/MED/42851232},
note = {CC BY-NC-SA},
}
RIS
TY - JOUR
TI - Seroprevalence of varicella antibodies in unvaccinated children with nephrotic syndrome in disease remission.
AU - Bharathidasan B
AU - Malika Yadav
AU - Aashima Dabas
AU - Anju Sharma
AU - Vikas Manchanda
AU - Mukta Mantan
PY - 2026
DA - 2026/08/01
JO - The Indian journal of medical research
DO - 10.25259/ijmr_734_2026
UR - https://europepmc.org/article/MED/42851232
AB - Background and objectives Varicella-zoster (VZV) virus infection can be severe in children with nephrotic syndrome. Lack of varicella vaccination through the national immunisation programme in India leaves many vulnerable to infection. We conducted this study to document the seroprevalence of Varicella antibodies in patients with nephrotic syndrome. Methods This cross-sectional study (Oct 2024-May 2025) was conducted at a tertiary-care teaching hospital in India, in children (1-18 y) with nephrotic syndrome (both steroid-sensitive and steroid-resistant) in disease remission. Serum VZV IgG antibodies were measured using the EUROIMMUN ELISA kit; titres ≥100 IU/L were considered seroprotective. Results 100 patients were enrolled (median age 8 y). None had received varicella vaccination, and only two reported prior infection. Overall seroprotection was 22% with a geometric mean titre of 9.472 IU/L [median (IQR) 7.59 (3.35; 73.38) IU/L]. No significant difference was observed in titres between steroid-sensitive and steroid-resistant nephrotic syndrome (P=0.532), but seroprotection increased with age (11.1% in <5 y to 33.3% in >10 y). Interpretation and conclusions Low seroprevalence likely reflects the inadequacy of natural immunity and absence of routine varicella vaccination, warranting larger seroprevalence studies and future research on the need for priority immunisation for this high-risk population.
SN - 0971-5916
ER -